SurLym trial: study protocol for a multicentre pragmatic randomised controlled trial on the added value of reconstructive lymphatic surgery to decongestive lymphatic therapy for the treatment of lymphoedema.

Devoogdt, Nele;De Vrieze, Tessa;Heroes, An-Kathleen;Bechter-Hugl, Beate;Thomis, Sarah;et.al.
(2024) BMJ open — Vol. 14, n° 5, p. e078114 [1-12] (2024)

Files

DevoogdtNBMJOpen2024.pdf
  • Open Access
  • Adobe PDF
  • 449.41 KB
Download

Details

Authors
  • Devoogdt, Neleorcid-logo
    Author
  • De Vrieze, Tessa
    Author
  • Heroes, An-Kathleen
    Author
  • Bechter-Hugl, Beate
    Author
  • Deltombe, ThierryUCLouvain
    Author
  • Frippiat, JacquelineUCLouvain
    Author
  • Servaes, MaximeUCLouvain
    Author
  • Berners, AlineUCLouvain
    Author
  • Fosseprez, Philippeorcid-logoUCLouvain
    Author
  • Krug, Brunoorcid-logoUCLouvain
    Author
  • Kayser, FrançoiseUCLouvain
    Author
  • Falticeanu, Ana AndreeaUCLouvain
    Author
  • Thomis, Sarahorcid-logo
    Author
Show more
Abstract
Lymphoedema is a chronic condition caused by lymphatic insufficiency. It leads to swelling of the limb/midline region and an increased risk of infection. Lymphoedema is often associated with mental and physical problems limiting quality of life. The first choice of treatment is a conservative treatment, consisting of exercises, skin care, lymph drainage and compression. Reconstructive lymphatic surgery is also often performed, that is, lymphovenous anastomoses, lymph node transfer or a combination. However, robust evidence on the effectiveness of reconstructive lymphatic surgery is missing. Therefore, the objective of this trial is to investigate the added value of reconstructive lymphatic surgery to the conservative treatment in patients with lymphoedema. A multicentre randomised controlled and pragmatic trial was started in March 2022 in three Belgian university hospitals. 90 patients with arm lymphoedema and 90 patients with leg lymphoedema will be included. All patients are randomised between conservative treatment alone (control group) or conservative treatment with reconstructive lymphatic surgery (intervention group). Assessments are performed at baseline and at 1, 3, 6, 12, 18, 24 and 36 months. The primary outcome is lymphoedema-specific quality of life at 18 months. Key secondary outcomes are limb volume and duration of wearing the compression garment at 18 months. The approach of reconstructive lymphatic surgery is based on presurgical investigations including clinical examination, lymphofluoroscopy, lymphoscintigraphy, lymph MRI or CT angiography (if needed). All patients receive conservative treatment during 36 months, which is applied by the patient's own physical therapist and by the patient self. From months 7 to 12, the hours a day of wearing the compression garment are gradually decreased. The study has been approved by the ethical committees of University Hospitals Leuven, Ghent University Hospital and CHU UCL Namur. Results will be disseminated via peer-reviewed journals and presentations. NCT05064176.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Devoogdt, N., De Vrieze, T., Heroes, A.-K., Bechter-Hugl, B., Fieuws, S., Godderis, L., Segers, K., Maleux, G., Deltombe, T., Frippiat, J., Servaes, M., Berners, A., Fosseprez, P., Krug, B., Kayser, F., Falticeanu, A. A., Randon, C., Monten, C., Van Landuyt, K., et al. (2024). SurLym trial: study protocol for a multicentre pragmatic randomised controlled trial on the added value of reconstructive lymphatic surgery to decongestive lymphatic therapy for the treatment of lymphoedema. BMJ open, 14(5), e078114 [1-12]. https://doi.org/10.1136/bmjopen-2023-078114 (Original work published 2024)